Your browser is no longer supported. Please, upgrade your browser.
Settings
IRWD Ironwood Pharmaceuticals, Inc. daily Stock Chart
IRWD [NASD]
Ironwood Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.30 Insider Own3.00% Shs Outstand160.07M Perf Week-1.23%
Market Cap1.42B Forward P/E19.47 EPS next Y0.46 Insider Trans-6.63% Shs Float152.45M Perf Month-16.89%
Income-199.40M PEG- EPS next Q0.09 Inst Own- Short Float12.30% Perf Quarter-20.04%
Sales367.30M P/S3.86 EPS this Y-135.70% Inst Trans2.11% Short Ratio12.08 Perf Half Y-25.72%
Book/sh-1.41 P/B- EPS next Y239.55% ROA-66.30% Target Price14.89 Perf Year-42.38%
Cash/sh- P/C- EPS next 5Y73.10% ROE111.40% 52W Range7.59 - 16.44 Perf YTD2.17%
Dividend- P/FCF- EPS past 5Y4.70% ROI-109.80% 52W High-46.10% Beta1.79
Dividend %- Quick Ratio2.00 Sales past 5Y72.20% Gross Margin89.50% 52W Low16.71% ATR0.44
Employees515 Current Ratio2.00 Sales Q/Q26.00% Oper. Margin-43.10% RSI (14)36.22 Volatility3.59% 4.97%
OptionableYes Debt/Eq- EPS Q/Q124.30% Profit Margin-64.50% Rel Volume1.02 Prev Close8.98
ShortableYes LT Debt/Eq- EarningsJul 30 AMC Payout- Avg Volume1.55M Price8.86
Recom2.40 SMA20-8.47% SMA50-13.92% SMA200-17.50% Volume1,582,060 Change-1.34%
Jul-10-19Resumed Credit Suisse Neutral
Mar-27-19Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-19Upgrade H.C. Wainwright Sell → Neutral $14
Jan-24-19Upgrade JP Morgan Underweight → Neutral
Nov-07-18Downgrade JP Morgan Neutral → Underweight
Nov-07-18Downgrade Credit Suisse Outperform → Neutral
Jul-23-18Initiated H.C. Wainwright Sell $12.50
May-09-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-18Downgrade BofA/Merrill Buy → Underperform
Dec-06-17Downgrade Mizuho Buy → Neutral $16
Jul-21-17Downgrade JP Morgan Overweight → Neutral
May-03-17Initiated Wells Fargo Outperform
Apr-07-17Reiterated Mizuho Buy $21 → $22
Feb-22-17Reiterated Barclays Equal Weight $13 → $16
Nov-04-16Reiterated Mizuho Buy $19 → $20
Oct-24-16Reiterated Wedbush Neutral $10 → $13
Oct-10-16Reiterated Mizuho Buy $24 → $19
Sep-27-16Reiterated WallachBeth Hold $15 → $17
Jul-15-16Reiterated Mizuho Buy $16 → $24
May-10-16Reiterated Mizuho Buy $15 → $16
Aug-13-19 04:50PM  Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment Business Wire
07:30AM  Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire
07:30AM  Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire
Aug-08-19 07:30AM  Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering Business Wire
Aug-06-19 04:05PM  Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes Business Wire
Aug-03-19 04:45AM  Edited Transcript of IRWD earnings conference call or presentation 30-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
Jul-31-19 10:58AM  Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates Zacks
06:00AM  Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know Motley Fool
04:24AM  Ironwood Pharmaceuticals Inc (IRWD) Q2 2019 Earnings Call Transcript Motley Fool
Jul-30-19 08:45PM  Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Top Estimates Zacks
04:01PM  Ironwood Pharmaceuticals Reports Second Quarter 2019 Results Business Wire
Jul-23-19 10:32AM  Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-19-19 12:15PM  Should You Be Concerned About Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Historical Volatility? Simply Wall St.
Jul-18-19 04:05PM  Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call Business Wire
Jun-21-19 06:09AM  100 Summer lands WeWork ahead of tower's possible sale American City Business Journals
Jun-20-19 07:09PM  Hedge Funds Have Never Been This Bullish On Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
09:40AM  Company News For Jun 20, 2019 Zacks
Jun-19-19 05:21PM  Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients Zacks
10:22AM  Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective Benzinga
Jun-18-19 04:05PM  Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C) Business Wire +8.08%
Jun-13-19 05:14PM  Cambridges Ironwood Pharma moving HQ to downtown Boston American City Business Journals
04:30PM  Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston Business Wire
Jun-05-19 09:50AM  Ironwood Initiates Dosing in Mid-Stage Study for MD-7246 Zacks
Jun-03-19 08:30AM  Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D Business Wire
Jun-01-19 09:32AM  Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report? Zacks
May-24-19 08:00PM  Sarissa Capital Is Drawn to Ironwood Pharmaceuticals Barrons.com
May-17-19 01:58PM  Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today Motley Fool +13.74%
May-16-19 04:07PM  6 Positions the Vanguard Health Care Fund Continues to Increase GuruFocus.com
04:55AM  Edited Transcript of IRWD earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-09-19 08:00AM  Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019 Business Wire
May-08-19 01:25PM  Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%? Simply Wall St.
May-07-19 04:05PM  Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference Business Wire
May-03-19 08:36AM  Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall Zacks
May-02-19 08:24PM  Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript Motley Fool -12.82%
12:13PM  Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ? Insider Monkey
09:35AM  Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:24AM  Ironwood: 1Q Earnings Snapshot Associated Press
07:00AM  Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance Business Wire
Apr-25-19 10:34AM  Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-18-19 04:05PM  Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call Business Wire
Apr-16-19 04:02PM  Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020 Business Wire
Apr-05-19 10:34AM  Will Ironwood Suffer From Dependence on Linzess' Progress? Zacks
Apr-02-19 06:23AM  As Ironwood spinout Cyclerion launches on the Nasdaq, CEO Hecht sees 'a fresh start' American City Business Journals
Apr-01-19 04:02PM  Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company Business Wire
Mar-27-19 02:56PM  Ironwood's new CEO has big plans for Linzess, but is mum on R&D American City Business Journals
Mar-16-19 10:07AM  Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Simply Wall St.
Mar-15-19 09:30AM  Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report? Zacks
Mar-14-19 04:54PM  Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement Business Wire
Mar-07-19 04:05PM  Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference Business Wire
Mar-04-19 04:05PM  Ironwood Pharmaceuticals to Present at Cowen Health Care Conference Business Wire
Feb-28-19 08:30AM  Recent Analysis Shows Yamana Gold, Broadcom Inc., Atlas Air Worldwide, Hawaiian, H&E Equipment Services, and Ironwood Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-26-19 09:00AM  Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering Business Wire
Feb-21-19 04:05PM  Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference Business Wire
Feb-14-19 10:02AM  Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise Zacks -5.63%
07:27AM  Edited Transcript of IRWD earnings conference call or presentation 13-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-13-19 05:17PM  Why Ironwood's Shares Climbed 11.7% on Wednesday Motley Fool +11.66%
03:29PM  Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:50AM  Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:52AM  Ironwood: 4Q Earnings Snapshot Associated Press
07:00AM  Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update Business Wire
Feb-10-19 05:37PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Feb-06-19 10:30AM  Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline Zacks
Jan-29-19 10:43AM  Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid Zacks
Jan-28-19 05:00PM  Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call Business Wire
08:30AM  Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation Business Wire
Jan-25-19 08:10AM  Investor Expectations to Drive Momentum within Hercules Capital, Alexandria Real Estate Equities, Ironwood Pharmaceuticals, 22nd Century Group, BorgWarner, and Forestar Group Discovering Underlying Factors of Influence GlobeNewswire
Jan-24-19 10:44AM  Ironwood Commences Phase I Study on IW-6463 for CNS Disorders Zacks
08:00AM  Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation Business Wire
07:45AM  The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial Benzinga
Jan-23-19 04:01PM  Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials Business Wire
Jan-17-19 05:14AM  How to spot risky biotech companies and six to avoid now MarketWatch
Jan-16-19 10:05AM  Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C Zacks
Jan-15-19 08:00AM  Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C Business Wire +6.19%
Jan-07-19 09:50AM  Ironwood to Get New CEO, Current CEO to Head Latest Spinoff Zacks +5.09%
Jan-06-19 05:00PM  Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer Business Wire
Jan-04-19 07:08PM  Ironwood Pharmaceuticals Picks AstraZeneca Executive to Be Next CEO The Wall Street Journal +11.34%
12:29PM  Ironwood co-founder, CEO will step down to head new spinout American City Business Journals
12:05PM  Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation Business Wire
11:01AM  Ironwood Pharmaceuticals Picks AstraZeneca Executive to Be Next CEO The Wall Street Journal
Jan-03-19 10:27AM  Ironwood/Allergan Settle Linzess Patent Litigation With Mylan Zacks
Jan-02-19 05:00PM  Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference Business Wire
04:03PM  Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation Business Wire
Dec-18-18 11:56PM  Hedge Funds Are Betting On Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
Dec-14-18 04:44PM  Edited Transcript of IRWD earnings conference call or presentation 6-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Dec-11-18 01:51PM  Is Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Overpaying Its CEO? Simply Wall St.
Dec-06-18 09:30AM  Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report? Zacks
Nov-12-18 07:35AM  Research Report Identifies Ironwood Pharmaceuticals, The AES, Accuray, Ball, Park Hotels & Resorts, and NeoGenomics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -5.13%
Nov-08-18 04:05PM  Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference Business Wire
09:56AM  Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down Zacks
Nov-06-18 09:30AM  Ironwood Pharmaceuticals (IRWD) Reports Q3 Loss, Misses Revenue Estimates Zacks -9.55%
08:25AM  Ironwood: 3Q Earnings Snapshot Associated Press
08:09AM  Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update Business Wire
Oct-30-18 09:31PM  Novartis May Beat Ironwood Pharmaceuticals to the Punch Motley Fool -18.09%
Oct-25-18 05:00PM  Ironwood Pharmaceuticals to Host Third Quarter 2018 Investor Update Call Business Wire +5.61%
Oct-19-18 10:05AM  Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs Zacks
Oct-12-18 01:15PM  Ironwood Pharmaceuticals Incs (NASDAQ:IRWD) Profit Outlook Simply Wall St.
Oct-11-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within Ironwood Pharmaceuticals, Erie Indemnity, ONEOK, Sterling Construction, Colgate-Palmolive, and ON Semiconductor New Research Emphasizes Economic Growth GlobeNewswire
Oct-08-18 08:00AM  Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting Business Wire
Sep-14-18 11:14AM  Ironwood Stock Up, Heart Candidate Gets Fast Track Status Zacks
08:00AM  Today's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Consylman GinaSVP, CFO & TreasurerAug 16Sale9.042121,916175,648Aug 20 05:37 PM
Gilbert Halley EChief Admin Officer & SVPJul 26Option Exercise4.8820,00097,600260,169Jul 30 04:48 PM
Gilbert Halley EChief Admin Officer & SVPJul 26Sale10.0020,000200,000240,169Jul 30 04:48 PM
OLANOFF LAWRENCE SDirectorJun 05Sale11.252,00022,50058,259Jun 07 04:06 PM
McHugh JulieDirectorJun 05Sale11.261,50016,890109,337Jun 07 04:05 PM
MCCOURT Thomas APresidentMay 10Sale10.534,05542,699107,239May 14 04:13 PM
Gilbert Halley EChief Admin Officer & SVPMay 10Sale10.534,05542,699238,240May 14 04:12 PM
Currie Mark GDirectorMay 10Sale10.534,05542,699528,903May 14 04:10 PM
Consylman GinaSVP, CFO & TreasurerMay 10Sale10.534,05542,699175,860May 14 04:08 PM
Currie Mark GChief Scientific OfficerMar 08Sale13.1549,500650,925528,480Mar 08 05:51 PM
Currie Mark GChief Scientific OfficerMar 07Sale13.29225,5002,996,895577,980Mar 08 05:51 PM
McHugh JulieDirectorMar 05Sale14.381,50021,57088,131Mar 06 04:07 PM
OLANOFF LAWRENCE SDirectorMar 05Sale14.412,00028,82037,553Mar 06 04:06 PM
Consylman GinaChief Financial OfficerFeb 21Sale14.3246659163,184Feb 22 04:47 PM
Currie Mark GChief Scientific OfficerFeb 21Sale14.3213186803,480Feb 22 04:49 PM
Gilbert Halley EChief Legal OfficerFeb 21Sale14.32851,217225,130Feb 22 04:51 PM
MCCOURT Thomas AChief Commercial OfficerFeb 21Sale14.324158783,309Feb 22 04:53 PM
MCCOURT Thomas AChief Commercial OfficerFeb 20Sale14.314,80068,68883,350Feb 22 04:53 PM
Gilbert Halley EChief Legal OfficerFeb 20Sale14.3110,157145,347225,215Feb 22 04:51 PM
Currie Mark GChief Scientific OfficerFeb 20Sale14.311,63123,340803,493Feb 22 04:49 PM
Consylman GinaChief Financial OfficerFeb 20Sale14.315,63180,580163,230Feb 22 04:47 PM
Gilbert Halley EChief Legal OfficerJan 30Option Exercise4.8920,44999,996235,372Jan 31 05:35 PM
Hecht Peter MChief Executive OfficerJan 25Option Exercise4.8950,000244,5004,726,468Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 25Sale12.2329,551361,4094,696,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 24Option Exercise4.8930,000146,7004,726,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 24Sale12.7030,000381,0004,696,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 23Option Exercise4.8930,000146,7004,726,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 23Sale12.6630,000379,8004,696,917Jan 25 06:24 PM
McHugh JulieDirectorDec 06Sale12.461,50018,69089,631Dec 10 04:56 PM
OLANOFF LAWRENCE SDirectorDec 06Sale12.472,00024,94039,553Dec 10 04:37 PM
Consylman GinaChief Financial OfficerNov 09Sale11.811,35816,03896,361Nov 13 09:41 PM
Currie Mark GChief Scientific OfficerOct 05Option Exercise10.85116,6511,265,465146,775Oct 09 06:42 PM
Currie Mark GChief Scientific OfficerOct 05Sale17.53116,6512,044,89230,124Oct 09 06:42 PM
Currie Mark GChief Scientific OfficerOct 04Option Exercise10.85116,6501,265,454146,774Oct 09 06:42 PM
Currie Mark GChief Scientific OfficerOct 04Sale18.09116,6502,110,67830,124Oct 09 06:42 PM
OLANOFF LAWRENCE SDirectorSep 05Sale19.102,00038,20041,553Sep 07 04:01 PM
McHugh JulieDirectorSep 05Sale19.101,50028,65091,131Sep 07 04:01 PM
Currie Mark GChief Scientific OfficerAug 24Option Exercise4.9565,000321,783840,000Aug 28 04:03 PM
Currie Mark GChief Scientific OfficerAug 24Sale18.3965,0001,195,350775,000Aug 28 04:03 PM
Currie Mark GChief Scientific OfficerAug 23Option Exercise4.9565,000321,784840,000Aug 24 05:21 PM
Currie Mark GChief Scientific OfficerAug 23Sale18.3965,0001,195,350775,000Aug 24 05:21 PM